|Trade names||Nestorone, Elcometrine, Annovera|
|Synonyms||SGA; SA; Nestorone; Nestoron; Elcometrine; ST-1435; AC-6844; CS-0411; 16-Methylene-17α-acetoxy-19-norprogesterone; 16-Methylene-17α-acetoxy-19-norpregn-4-ene-3,20-dione|
|Subcutaneous implant, vaginal ring, transdermal patch|
|Drug class||Progestin; Progestogen; Progestogen ester|
|Protein binding||95% (to albumin and not to SHBG|
|Metabolism||Hydroxylation (CYP3A4), reduction (5α-reductase)|
|Elimination half-life||Vaginal ring: 4.5 hours|
Parenteral: 24–72 hours
Oral: 1–2 hours
|Chemical and physical data|
|Molar mass||370.482 g/mol g·mol−1|
|3D model (JSmol)|
Segesterone acetate (SGA), sold under the brand names Nestorone, Elcometrine, and Annovera, is a progestin medication which is used in birth control and in the treatment of endometriosis in the United States, Brazil, and other South American countries. It is available both alone and in combination with an estrogen. It is not effective by mouth and must be given by other routes, most typically as a vaginal ring or implant that is placed into fat.
Side effects of SGA are similar to those of other progestins. SGA is a progestin, or a synthetic progestogen, and hence is an agonist of the progesterone receptor, the biological target of progestogens like progesterone. It has some affinity for the glucocorticoid receptor and has no other important hormonal activity.
SGA was developed by the Population Council and was introduced for medical use by 2000. It is under development in the United States and Europe as a gel in combination with estradiol or testosterone for use as a method of birth control in women and in men, respectively. On August 10, 2018, a first-of-its-kind one-year contraceptive vaginal ring containing segesterone acetate in combination with ethinyl estradiol was approved in the United States. It is marketed under the brand name Annovera and is reusable for up to one year as a method of birth control in women. Annovera will not require refrigeration which is very useful for low resource areas.
SGA acts primarily as a high-affinity agonist of the progesterone receptor (272% of the affinity of progesterone and 136% of that of promegestone). It does not bind significantly to the androgen receptor, estrogen receptor, or mineralocorticoid receptor. As such, SGA does not have estrogenic, androgenic, antiandrogenic, or antimineralocorticoid activity. However, SGA does have significant affinity for the glucocorticoid receptor (38% of that of dexamethasone), but in spite of its relatively high affinity for the glucocorticoid receptor, it either does not have any glucocorticoid effects or shows glucocorticoid effects only at exceptionally high doses in animals. SGA has no antiglucocorticoid activity in animals either. The ovulation-inhibiting dosage of parenteral SGA has been reported to be 0.15 mg per day, while the endometrial transformation dosage has been reported to be 0.6 mg per cycle. SGA has antigonadotropic effects and functional antiestrogenic effects via its progestogenic activity similarly to other progestogens.
SGA is only weakly active orally, and is instead given as a subcutaneous implant. The oral bioavailability of SGA has been reported to be only 10%. However, it has also been reported that the medication is more than 100-fold as potent when delivered via subcutaneous implant relative to oral administration in rats. SGA is bound to albumin. It does not bind to sex hormone-binding globulin. Segesterone, the deacetylated form of SGA, is a metabolite of the medication. The biological half-life of parenteral SGA has been reported to be 24 to 72 hours. One study specifically reported a biological half-life of 26.8 hours. It has been reported that the biological half-life of SGA with oral administration is only 1 to 2 hours. In contrast to all of the preceding however, the Food and Drug Administration (FDA) label for Annovera, a one-year vaginal ring containing ethinylestradiol and SGA, lists a circulating half-life of SGA of 4.5 hours.
SGA, also known as 16-methylene-17α-acetoxy-19-norprogesterone or as 16-methylene-17α-acetoxy-19-norpregn-4-ene-3,20-dione, is a synthetic norpregnane steroid and a derivative of progesterone. It is a combined derivative of 17α-hydroxyprogesterone and 19-norprogesterone, or a derivative of gestronol (17α-hydroxy-19-norprogesterone). The medication is the C17α acetate ester of segesterone, which, in contrast, was never marketed. Other 19-norprogesterone derivatives include demegestone, gestonorone caproate (norhydroxyprogesterone caproate), nomegestrol acetate, promegestone, and trimegestone. SGA is a derivative of 16-methylene-17α-hydroxyprogesterone acetate, and is the analogue of methenmadinone acetate without the C19 methyl group or the C6 double bond. A derivative of SGA with even greater progestogenic potency in comparison to SGA is 18-methylsegesterone acetate.
Society and culture
Segesterone acetate is the generic name of the drug and its USAN. It is also known by its brand names nestorone and elcometrine, as well as by its former developmental code names ST-1435, AC-6844, and CS-0411.
SGA is available alone in several South American countries, including Brazil. It was not available in the United States previously, but is now available in this country as a contraceptive vaginal ring in combination with ethinylestradiol.
A combination of SGA and the estrogen estradiol is under development in a transdermal gel formulation for use as a contraceptive in women by the Population Council in conjunction with Antares Pharma in the United States and Europe. As of December 2017, it is in phase III clinical trials for this indication. The medication has the tentative brand name NestraGel. A combination of SGA and the estrogen ethinylestradiol is under development in a vaginal ring formulation for use as a one-year contraceptive by the Population Council in multiple regions including Latin America, Europe, and Australia. It has completed phase III clinical trials and efforts are underway to pursue regulatory approval. It was approved in the United States in August 2018.
A combination of SGA and the androgen testosterone is under development as a transdermal gel formulation for use as a hormonal contraceptive in men by the Population Council. As of December 2017, it is in phase II clinical studies for this purpose.
- Thomas L. Lemke; David A. Williams; Victoria F. Roche; S. William Zito (24 January 2012). Foye's Principles of Medicinal Chemistry. Lippincott Williams & Wilkins. p. 1403. ISBN 978-1-60913-345-0. Retrieved 13 September 2012.
- A.R. Genazzani (15 May 2001). Hormone Replacement Therapy and Cardiovascular Disease: The Current Status of Research and Practice. CRC Press. pp. 95–. ISBN 978-1-84214-038-3.
- Kuhl, H (2005). "Pharmacology of estrogens and progestogens: influence of different routes of administration" (PDF). Climacteric. 8 (sup1): 3–63. doi:10.1080/13697130500148875. ISSN 1369-7137. PMID 16112947.
- Rabe, T., Goeckenjan, M., Ahrendt, H. J., Crosignani, P. G., Dinger, J. C., Mueck, A. O., ... & Strowitzki, T. (2011). Oral Contraceptive Pills: Combinations, Dosages and the Rationale behind 50 Years or Oral Hormonal Contraceptive Development. Journal für Reproduktionsmedizin und Endokrinologie-Journal of Reproductive Medicine and Endocrinology, 8(1), 58-129. http://www.kup.at/kup/pdf/10166.pdf
- Fraser IS, Weisberg E, Kumar N, Kumar S, Humberstone AJ, McCrossin L, Shaw D, Tsong YY, Sitruk-Ware R (December 2007). "An initial pharmacokinetic study with a Metered Dose Transdermal Systemfor delivery of the progestogen Nestorone as a possible future contraceptive". Contraception. 76 (6): 432–8. doi:10.1016/j.contraception.2007.08.006. PMID 18061700.
- Croxatto, H (2000). "Progestin implants". Steroids. 65 (10–11): 681–685. doi:10.1016/S0039-128X(00)00124-0. ISSN 0039-128X.
- Sanjay Rajagopalan; Debabrata Mukherjee; Emile R. Mohler (31 August 2004). Manual of Vascular Diseases. Lippincott Williams & Wilkins. p. 803. ISBN 978-0-7817-4499-7. Retrieved 13 September 2012.
- Hussain R, El-Etr M, Gaci O, et al. (October 2011). "Progesterone and Nestorone facilitate axon remyelination: a role for progesterone receptors". Endocrinology. 152 (10): 3820–31. doi:10.1210/en.2011-1219. PMID 21828184.
- Kumar N, Koide SS, Tsong Y, Sundaram K (2000). "Nestorone: a progestin with a unique pharmacological profile". Steroids. 65 (10–11): 629–36. doi:10.1016/S0039-128X(00)00119-7. PMID 11108869.
- Prasad, P. V., & Shrivastav, T. G. (2015). Nestorone®: A new hope for Gynecologists, Andrologists and Neurologists. of, 3, 2.
- Ilani N, Roth MY, Amory JK, Swerdloff RS, Dart C, Page ST, Bremner WJ, Sitruk-Ware R, Kumar N, Blithe DL, Wang C (2012). "A new combination of testosterone and nestorone transdermal gels for male hormonal contraception". J. Clin. Endocrinol. Metab. 97 (10): 3476–86. doi:10.1210/jc.2012-1384. PMC 3462927. PMID 22791756.
- Prasad PV, Bashir M, Sitruk-Ware R, Kumar N (2010). "Single-dose pharmacokinetics of Nestorone, a potential female-contraceptive". Steroids. 75 (3): 252–64. doi:10.1016/j.steroids.2009.12.011. PMID 20064539.
- G.W.A Milne (1 November 2017). Ashgate Handbook of Endocrine Agents and Steroids. Taylor & Francis. pp. 158–. ISBN 978-1-351-74347-1.
- Tuba Z, Bardin CW, Dancsi A, Francsics-Czinege E, Molnár C, Csörgei J, Falkay G, Koide SS, Kumar N, Sundaram K, Dukát-Abrók V, Balogh G (May 2000). "Synthesis and biological activity of a new progestogen, 16-methylene-17alpha-hydroxy-18-methyl-19-norpregn-4-ene-3, 20-dione acetate". Steroids. 65 (5): 266–74. doi:10.1016/S0039-128X(99)00109-9. PMID 10751638.
- Sitruk-Ware R, Small M, Kumar N, Tsong YY, Sundaram K, Jackanicz T (November 2003). "Nestorone: clinical applications for contraception and HRT". Steroids. 68 (10–13): 907–13. doi:10.1016/S0039-128X(03)00140-5. PMID 14667982.
- Kumar N, Fagart J, Liere P, Mitchell SJ, Knibb AR, Petit-Topin I, Rame M, El-Etr M, Schumacher M, Lambert JJ, Rafestin-Oblin ME, Sitruk-Ware R (January 2017). "Nestorone® as a Novel Progestin for Nonoral Contraception: Structure-Activity Relationships and Brain Metabolism Studies". Endocrinology. 158 (1): 170–182. doi:10.1210/en.2016-1426. PMC 5412978. PMID 27824503.
- Martin Negwer; Hans-Georg Scharnow (2001). Organic-chemical drugs and their synonyms: (an international survey). Wiley-VCH. ISBN 978-3-527-30247-5. Retrieved 13 September 2012.